• Home / Conformable GORE® TAG® Thoracic Endoprosthesis /

Advancing endovascular therapy to treat thoracic diseases of today and tomorrow

Conformable GORE® TAG® Thoracic Endoprosthesis

The GORE® TAG® Device has remained the leading option for less invasive treatment of thoracic aneurysms, transections, and Type B dissections. Today, the Conformable GORE® TAG® Thoracic Endoprosthesis is supported by experience, proven durability, and a design that has set the standard for conformability without compromise.


  • Proven clinical results supported by more than 16 years of TEVAR experience
  • More than 83,000 devices distributed worldwide1
  • The most studied thoracic endograft available2


  • Designed to treat aneurysms, transections, and all Type B dissections
  • Proven compression resistance3
  • Sealing cuffs increase security against endoleaks


  • Optimized wall apposition in angulated arch anatomies
  • Provides optimal radial force to treat compromised aortas
  • Accommodates a wide range of aortic anatomies

As we work toward the next evolution of the Conformable GORE® TAG® Thoracic Endoprosthesis, you can count on our commitment to provide innovative solutions intended to maximize patient outcomes.

Find out more about the entire
family of Aortic Accessories

1 Data on file
2 With the first clinical implant occurring in 1998, the GORE® TAG® Device has been studied in ten FDA approved clinical studies, one European clinical trial (ADSORB), and one worldwide registry (GREAT)
3 “No reports of compression with more than 28,000 devices distributed worldwide“ Through January 17, 2014. GORE® TAG® Device, Annual Clinical Update, 2014 not published.